At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
The endorsement follows overwhelming support for the share swap preceding the merger,
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Subscribe To Our Newsletter & Stay Updated
